Novartis Casts It Immuno-Oncology Nets Wider As PD1 Catch Gets Away
Novartis has revealed a series of deals which widen its net in immune-oncology, and hopefully compensate for falling behind some of its competitors in this key development area.
Novartis has revealed a series of deals which widen its net in immune-oncology, and hopefully compensate for falling behind some of its competitors in this key development area.